The Latest Cardiac and Vascular News
DRAPER, Utah–(BUSINESS WIRE)–Xenter, Inc. (Xenter.io) announced the recent unveiling of its groundbreaking dual sensor investigational guidewire for TAVR procedures at the Transcatheter Cardiovascular Therapeutics (TCT) 2023 conference in San Francisco, CA. Xenter introduced the first-of-its-kind wireless guidewire designed for use during transcatheter aortic valve replacement (TAVR) procedures that aims to collect an extensive range of crucial real-time data points to serve as an aortic regu
BELLEVUE, Wash., Nov. 08, 2023 (GLOBE NEWSWIRE) — Today Truveta announced the availability of more than 56.6 million clinical observations from more than 2.7 million echocardiogram reports from more than 1.7 million de-identified patients, making it the market leader in real-world data to advance cardiovascular research at scale. Truveta delivers […]
Radiology can now focus efforts on identification and diagnosis—and not be distracted by follow-up tracking. OVERLAND PARK, Kan., Nov. 7, 2023 /PRNewswire/ — Softek Illuminate, Inc., a provider of enterprise follow-up management and discovery software, announces the ability of their…
CHICAGO–(BUSINESS WIRE)–Family Medicine Specialists has selected Cardio Diagnostics’ tests to identify patients at risk for coronary heart disease events.
SINGAPORE, Nov. 7, 2023 /PRNewswire/ — Nuevocor, a pre-clinical stage biotechnology company focused on developing cardiac genetic medicines through a unique platform to understand the mechanobiological causes of disease, announced today a pair of presentations at two major meetings, the…
SANTA CLARA, Calif.–(BUSINESS WIRE)–HeartBeam Granted Third US Patent for 12-Lead Extended Wear Patch for Detecting Heart Attacks and Complex Cardiac Arrythmias
32-year career in medical device and electrophysiology business expansion for industry bellwethers; led multiple company exits including a $1B sale in 2018 Part of leadership team that grew Johnson & Johnson’s original cardiology/electrophysiology business from $22M to $500M in 7 years Westport, CT, Nov. 07, 2023 (GLOBE NEWSWIRE) — Westport, […]
BURLINGTON, Mass.–(BUSINESS WIRE)–Cardurion Pharmaceuticals, Inc. (“Cardurion” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of novel, next-generation therapeutics for the treatment of cardiovascular diseases, today announced that the Company will present preclinical data on its Calcium/Calmodulin-dependent Protein Kinase II (CaMKII) inhibitor program at the American Heart Association’s (AHA) Scientific Sessions 2023. Cardurion is the first
HOLTE, Denmark, Nov. 6, 2023 /PRNewswire/ — ResoTher Pharma, a biotech company focused on developing life-saving options for patients suffering from cardiovascular disease, today announced that the company has received a €2.5 million grant from the European Innovation Council (EIC) to…
PRINCETON, N.J.–(BUSINESS WIRE)—- $BMY #BMS–Bristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
